A single-arm, multi-center, exploratory safety and efficacy study of FCR001 cell-based therapy to induce donor-specific tolerance in previously transplanted recipients of a kidney from a living donor, and safety in FCR001 donors(the FREEDOM-2 study)
|Effective start/end date||4/1/22 → 4/1/29|
- TALARIS THERAPEUTICS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.